University of Minnesota
https://twin-cities.umn.edu/
612-625-5000
Milestone
4.1.d

Review of novel platforms

In progress
High priority

Convene a workshop to review the scientific challenges and recent advancements in development of novel vaccine platforms to determine how best to guide R&D for broadly protective influenza vaccines for regulatory approval, global scale-up, and rapid deployment in response to pandemic influenza viruses.

Progress Highlights

Although a workshop has not been convened, interest in applying novel platforms to seasonal influenza vaccines is evident; 10 mRNA-based next-generation influenza vaccine candidates are now in clinical development 

See Vaccine Technology Landscape


Kok 2024 developed a high-resolution antigenic map of the global antigenic evolution of avian influenza A(H5) HA to engineer 30 vaccine HA antigens designed to elicit Ab responses that broadly cover the A(H5) antigenic space.

See research